10-K: Bioxytran Inc. Reports Full Year 2023 Results, Outlines Progress in Drug Development

Bioxytran, Inc. released its 2023 annual report, detailing financial results and advancements in its BXT-25 and ProLectin-Rx drug development programs.

Summary

• Bioxytran, Inc., a clinical-stage pharmaceutical company, is focused on developing therapies for hypoxia and viral diseases.
• The company's lead drug candidate, BXT-25, is designed to treat hypoxic conditions in the brain resulting from stroke.
• Pharmalectin, a subsidiary, is developing ProLectin-Rx, a galectin inhibitor for treating viral diseases, including COVID-19.
• The company reported a net loss of $4,280,002 for the year ended December 31, 2023, compared to a net loss of $2,463,932 in 2022.
• Research and development expenses totaled $1,149,209 in 2023, up from $977,768 in 2022.
• General and administrative expenses increased to $2,473,386 in 2023 from $977,962 in 2022.
• The company has an accumulated deficit of $15,497,602 as of December 31, 2023.
• Bioxytran is seeking additional funding of $30-35 million to complete Phase II/a trials for ProLectin-A and BXT-25 and Phase II/b/III trials for ProLectin-I and -F.
• The company has convertible notes outstanding with a principal amount of $1,900,000 and accrued interest of $223,759 as of December 31, 2023.

Sentiment

Score: 4

Explanation: The document highlights promising drug development progress and regulatory approvals, but the significant financial losses, negative working capital, and need for substantial additional funding temper the overall sentiment. The company faces significant financial challenges and risks.

Positives

• The company has made progress in developing its lead drug candidates, BXT-25 and ProLectin-Rx.
• The FDA has approved an IND for ProLectin-M, allowing human trials to proceed.
• BXT-25 has shown promising results in animal testing, indicating non-toxicity.
• The company has a scientific and medical advisory board consisting of leading experts.
• The company has a clear strategy to license its drugs to large pharmaceutical companies.

Negatives

• The company has incurred significant net losses, with a net loss of $4,280,002 in 2023.
• The company has a negative working capital of $3,223,414 as of December 31, 2023.
• The company has convertible notes outstanding with a principal amount of $1,900,000 and accrued interest of $223,759.
• The company needs to raise an additional $30-35 million to complete clinical trials.
• The company has not yet generated any revenue from operations.

Risks

• The company has a limited operating history, making it difficult to evaluate its future prospects.
• The company will require additional financing to implement its business plan, which may not be available.
• Raising additional capital may cause dilution to existing stockholders.
• The company's products are based on novel, unproven technologies.
• Clinical drug development is a lengthy and expensive process with an uncertain outcome.
• The company may be unable to commercialize its drug candidates.
• The company's competitive position depends on the protection of its intellectual property.
• The company may become involved in lawsuits to protect or enforce its patents.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company plans to advance its drug candidates through regulatory submissions and clinical trials, seeking strategic partnerships for commercialization. They intend to raise additional capital through private placements and public offerings.

Management Comments

• Management plans to seek additional capital through private placements and public offerings of its Common Stock.
• Management believes that if they can raise $3,700,000, they will have sufficient working capital to develop their business over the next approximately fifteen months.

Industry Context

The company operates in the pharmaceutical industry, focusing on novel therapies for hypoxia and viral diseases. The market for stroke and COVID-19 treatments is large and competitive, with significant unmet medical needs.

Comparison to Industry Standards

• The company's approach to using co-polymer technology for oxygen therapeutics is novel compared to traditional methods like blood transfusions or hyperbaric oxygen therapy.
• The company's focus on galectin antagonists for viral infections is unique, as most current treatments are repurposed therapeutics.
• The company's development of both oral and intravenous treatments for COVID-19 is comprehensive compared to other companies focusing on single treatment modalities.
• The company's reliance on third-party manufacturing facilities is common in the biotech industry, especially for smaller companies.
• The company's need for additional funding is typical for clinical-stage pharmaceutical companies, as drug development is capital-intensive.

Related Party Transactions

• On April 14, 2023, 6,763,562 shares of Common Stock were issued to offset an affiliate against invoices paid on behalf of the Company and accrued salaries to our Officers, for a total value of $2,164,340.
• On September 14, 2023, 5,824,741 shares of Common Stock were exchanged by the Company's officers for invoices and salary past due in the amount of $786,340.
• On January 18, 2024, the Company issued 3,599,289 shares of Common Stock at a value of $485,904.

Stakeholder Impact

• Shareholders face the risk of dilution from potential capital raises.
• Employees are subject to the company's financial stability and ability to continue operations.
• Customers (potential patients) may benefit from the development of new therapies.
• Suppliers and creditors are exposed to the company's financial risks.
• The company's success could have a positive impact on the healthcare industry.

Next Steps

• The company intends to proceed with a 14-day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats.
• The company plans to start clinical trials for ProLectin-M in the first quarter of 2024.
• The company will seek additional funding to complete clinical trials for its drug candidates.
• The company will continue to develop new and proprietary drug candidates.

Key Dates

Keywords

Bioxytran, BXT-25, ProLectin-Rx, hypoxia, stroke, COVID-19, galectin inhibitor, clinical trials, pharmaceutical, drug development